Rhesus macaques were immunized with live vaccinia virus recombinants expressing the envelope glycoproteins (gp7O and gp22) of simian type D retrovirus (SRV), serotype 1 or 3. All of the animals immunized with either the SRV-1 env or the SRV-3 env vaccinia virus recombinant developed neutralizing antibodies against the homologous SRV. In addition, both groups developed cross-reactive antibodies and were protected against an intravenous live-virus challenge with SRV-1. The four control animals immunized with a vaccinia virus recombinant expressing the G protein of respiratory syncytial virus were not protected against the same SRV-1 challenge. Although SRV-1 and SRV-3 immune sera showed cross-neutralization, they failed to neutralize a separate, more distantly related serotype, SRV-2, in an in vitro assay. These findings are consistent with the known degree of serologic and genetic relatedness of these three SRV strains.
A naturally occurring immunodeficiency disease of Asian macaques is caused by a family of infectiously transmitted type D retroviruses (for a summary, see reference 11). These simian type D retroviruses (SRVs) are classified into five distinct neutralization serotypes, 1 through 5 (7, 24, 25, 31) , but they seem to use a common cell surface receptor (29) . SRV infection is prevalent in wild-caught and colony-bred macaques and is one of the leading causes of death among species of Asian macaques in several United States primate research centers (10) . The prototype type D retrovirus was isolated in 1970 from a spontaneous breast tumor in a rhesus monkey (Macaca mulatta) and was called Mason-Pfizer monkey virus (M-PMV) (16) . Experimental transmission of M-PMV into young rhesus monkeys at that time showed that it was nononcogenic but instead was immunosuppressive (8) . These findings were later confirmed by the reisolation of M-PMV from the frozen primary tumor and experimental induction of fatal immunodeficiency disease in young rhesus monkeys (5) . In cross-neutralization studies with rhesus monkey antisera, M-PMV was more closely related to SRV-1 than to SRV-2 (24) . M-PMV was thus designated SRV-3 and will be referred to as such in this article. SRV-1, SRV-2, and SRV-3 have each been molecularly cloned and totally sequenced (27, 30, 32) , and fatal immunodeficiency has been induced with the cloned SRV-1 (13) . In keeping with its partial serologic relatedness to SRV-1, the env amino acid sequence of SRV-3 was found to be more closely related to that of SRV-1 than that of SRV-2 (32) . In the surface (SU) domain of the env gene, SRV-1 and SRV-3 have 83% identity, whereas SRV-2 has 58% identity with either SRV-1 or SRV-3.
The physical contact, most likely by the percutaneous inoculation of cell-free virus in saliva via biting and scratching (20) . Natural resistance to SRV-induced disease correlates with the development of neutralizing antibodies to the surface and transmembrane envelope glycoproteins, gp7O and gp2O, respectively (18 of 500 ,ug of 5-bromo-4-chloro-3-indolyl-13-D-galactopyranoside (Sigma, St. Louis, Mo.) per ml were generated by published protocols (22, 23) . One of these was picked for each recombinant and purified by two more successive rounds of infection and selection. A final purified plaque was used to produce a small stock of each recombinant virus. The SRV-3 recombinant was designated Vac.SRV-3.env, and the SRV-1 recombinant was similarly termed Vac.SRV-1.env. Virus stock titers were determined on CV-1 cells as described before (6) .
Recombinant vaccinia viruses were assayed for their ability to express and process the Pr86env precursor protein of the SRVs to the mature surface (gp7O) and cell-associated transmembrane (gp22) glycoproteins in a metabolic labeling experiment. At 5 h postinfection (p.i.), CV-1 cells infected with either Vac.SRV-3.env or Vac.SRV-1.env were labeled in a 15-min pulse with [3H]leucine and then chased in unlabeled medium for 4 h. This chase period has been shown previously to be sufficient for conversion of a majority of Pr86 to gp7O and gp22 glycoproteins in CV-1 cells infected with simian virus 40 recombinant virions expressing the M-PMV envelope glycoprotein gene (2) . The results of this protein expression experiment are shown in Fig. 1 , where it can be seen that the precursor protein is processed normally to gp7O and gp22 when expressed from the vaccinia virus vector. Recognition by the goat antiserum of the Vac.SRV-1.env proteins is somewhat reduced in comparison to those of Vac.SRV-3.env owing to the use of SRV-3 as the antigen. However, recognition of gp22 is similar in both, presumably because of the high degree of amino acid sequence homology between the transmembrane (TM) glycoproteins of SRV-1 and SRV-3. In the absence of the SRV proteinase and virus assembly, the gp22 protein is not further processed to the normally virus-associated gp2O (4); nevertheless, these surface-expressed glycoproteins can induce cell-cell fusion in Raji cells infected with either vaccinia virus recombinant (3).
Recombinant vaccinia viruses were grown and purified for animal vaccination by sucrose gradient centrifugation as described previously (14, 21 Three rhesus macaques received the vaccinia virus-SRV-1 env recombinant (Vac.SRV-l.env), four received the vaccinia virus-SRV-3 env recombinant (Vac.SRV-3.env), and four controls received the respiratory syncytial virus recombinant (Vac.RSV.G). All animals were immunized three times, at weeks -14, -8, and -2 from date of challenge, with 108 PFU of the respective vaccinia virus recombinants by skin scarification. On day 0, all monkeys were inoculated intravenously with 1.5 ml containing 2 x 105 syncytiuminducing units of SRV-1.
SRV-1-specific antibody titers of 1:100 to 1:200 were detected in both groups of SRV-immunized animals at 3 weeks after the first boost (-5 weeks) ( Table 1) . On the day of live-virus inoculation (day 0), which was 2 weeks after the second boost, the ELISA titers were 1:200 to 1:400 for all seven SRV vaccinates except one of the SRV-3 vaccinates, for which the ELISA titer was <1:100. Western blot analysis done on the day of challenge showed that all SRV-vacci- nated monkeys had strong antibody reactions against the two SRV-1 envelope glycoproteins, gp7O and gp2O ( Fig. 2A) . In all SRV vaccinates, low titers of neutralizing antibody (1:2 to 1:8) were first detected 1 week after the second boost (-1 week) ( (Tables 1 and 2 ). Increases in neutralizing antibody titer against the heterologous virus after challenge were less marked. After challenge, no increased staining density was observed in the Western blots from the protected animals ( Fig. 2) and no significant reactivity to core proteins could be detected. None of the SRV-1 or SRV-3 immune sera were able to neutralize SRV-2 in vitro (data not shown). At 2 months following challenge, the SRV-1-specific T-cell proliferative responses had increased severalfold (S.I. = 3.0 to 6.0) in three of four SRV-1 and two of four SRV-3 env vaccinates (data not shown). At 3 months p.i., the two persistently infected control animals were ill with immunodeficiency disease, whereas all other animals remained healthy.
These results demonstrate that immunization of rhesus macaques with live recombinant vaccinia virus expressing the envelope glycoproteins of either SRV-1 or SRV-3 protects against challenge infection with SRV-1. Cross-protection in vivo is correlated with the vaccine induction of cross-reacting SRV-1 and SRV-3 binding and neutralizing antibody in vitro. The rise in SRV-1 neutralizing antibody titer occurring soon after challenge in most of the protected vaccinates (Table 2) suggests that a transient infection occurred but was promptly cleared by the immunized animals. The lack of established infection in the protected animals is also indicated by the absence of antibody to the viral core protein (p27) on Western blot (Fig. 2B) and the failure to isolate virus from PBMC (Table 3) . These findings extend those made previously with the vaccinia virus-SRV-2 envelope vaccine (15) and indicate that the envelope glycoproteins of SRV-1 and SRV-3 are also sufficient for eliciting protective immunity against SRV-1.
The degree of humoral immunity induced by these vaccines was similar to that found in animals convalescing from SRV-1 and SRV-3 infection (18) and was sufficient to confer protection against a high challenge dose of SRV-1. The results confirm the serologic relatedness of SRV-1 and SRV-3 previously shown by cross-neutralization in vitro (24) by showing cross-protection of SRV-3 env-vaccinated monkeys against SRV-1 in vivo. The lack of close relatedness of these serotypes with SRV-2 is demonstrated by the absence of cross-neutralization of SRV-2 by the SRV-1 and SRV-3 immune sera. Although SRV-1 and SRV-3 env vaccines should cross-protect against each other, neither of these vaccines would be expected to protect against infection with the serologically distinct SRV-2 strain.
Our results confirm that, in contrast to infections with lentiviruses such as human and simian immunodeficiency (25) .
other successful vaccines, including the SRV-1 inactivated whole virus (26) and vaccinia virus-SRV-2 env recombinant (15) , immune protection has similarly occurred after transient infection from the challenge virus. Indeed, strong, lasting immunity in these SRV-vaccinated monkeys will probably result from this initial infection that is successfully cleared by the immunized animals. However, in the present study, the duration of immunity remains to be determined.
The control of SRV infection in macaques in captivity, particularly in breeding colonies, is an urgent need from both the practical and scientific viewpoints. This goal can be accomplished by a test and removal program, which, however, requires serial assays for type D retrovirus antibodies and infectious virus (19) . It should also now be possible to protect macaques from natural infection with SRV-1, SRV-2, or SRV-3, the most common serotypes in U.S. primate facilities (10), by using a polyvalent vaccinia virus vaccine expressing SRV-2 and either SRV-1 or SRV-3 envelope glycoproteins.
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